Irinotecan/floxuridine liposomal

Drug Profile

Irinotecan/floxuridine liposomal

Alternative Names: CPX-1; Floxuridine/irinotecan; Irinotecan HCl:Floxuridine; Irinotecan:Floxuridine; Liposomal irinotecan/floxuridine

Latest Information Update: 11 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Celator Pharmaceuticals
  • Class Antineoplastics; Camptothecins; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Antimetabolites; DNA topoisomerase I inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Colorectal cancer

Most Recent Events

  • 13 Aug 2015 Phase-II development is ongoing in USA and Canada
  • 17 Mar 2015 Celator Pharmaceuticals has patent protection for irinotecan/floxuridine in Japan (Celator Pharmaceuticals 10-K, March 2015)
  • 01 Apr 2013 Irinotecan/floxuridine is still in phase II trials for Colorectal cancer (second-line therapy or greater, late-stage disease) in Canada and the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top